2 results
Approved WMORecruitment stopped
• To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects with LCA or RP caused by RPE65 or LRAT gene mutations who have been treated previously with a single 7-day course of QLT091001 in…
Approved WMOWill not start
The overall objectives of the study are to evaluate the long-term safety and durability of GT005 in participants with GA secondary to AMD who have been treated in an antecedent study.